Idera Pharmaceuticals Announces Several Key Leadership Additions
November 30 2015 - 8:00AM
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage
biopharmaceutical company developing toll-like receptor and RNA
therapeutics for patients with cancer and rare diseases, today
announced several key leadership additions as the company continues
to build the organization to support its clinical development
initiatives and organizational growth. Idera has appointed
Mark J. Cornfeld, M.D., M.P.H., as Vice President and Medical Lead,
Oncology; Kirsten L. Gruis, M.D., M.S., as Senior Medical Director,
Rare Diseases; Tanya N. Lewis, Vice President, Regulatory Affairs
and Quality Assurance and John J. Kirby, Vice President, Corporate
Accounting.
“As we pursue our purpose of helping patients suffering from
cancer or rare diseases, it is imperative that we continue to
recruit outstanding talent,” stated Vincent Milano, Idera
Pharmaceuticals Chief Executive Officer. “Mark, Kirsten,
Tanya and John are all highly qualified in their respective areas
of expertise and of equal importance are perfect fits for the
culture that we are building at Idera.”
Dr. Cornfeld most recently served in various oncology leadership
roles at GSK including lead physician for afuresertib and clinical
development lead as well as Director of Global Oncology Research
and Development. Prior to joining GSK, Dr. Cornfeld also held
roles of increasing responsibility at Johnson & Johnson and
Hoffman-LA Roche. Prior to joining industry, Dr. Cornfeld
held oncology leadership roles at several medical centers including
the Fox Chase Cancer Center in Philadelphia, PA. Dr. Cornfeld
received his M.D. from the University of Pennsylvania, M.P.H. from
Rutgers University and his Bachelor of Arts from the University of
Pennsylvania.
Dr. Gruis most recently served as Director, Clinical Development
at Alnylam Pharmaceuticals where she served as clinical lead for
the Phase 3 program of Patisiran for familial amyloidotic
polyneuropathy (FAP). Prior to joining Alnylam, Dr. Gruis
served as a Neuromuscular Clinical Lead at Pfizer. Dr. Gruis
received her M.D. from the University of Iowa, M.S. from the
University of Michigan and her Bachelor of Science from Iowa State
University.
Ms. Lewis most recently served as Vice President of Regulatory
Affairs and Medical Writing at Tesaro, Inc. Prior to joining
Tesaro, Ms. Lewis held regulatory roles of increasing
responsibility at Seaside Therapeutics, Vion Pharmaceuticals,
Millenium Pharmaceuticals and Genzyme Corporation. Ms. Lewis
received her M.S. from the Massachusetts College of Pharmacy and
Allied Health Sciences and her Bachelor of Science from
Northeastern University.
Mr. Kirby most recently served as Assistant Controller at Endo
Pharmaceuticals. Prior to joining Endo, Mr. Kirby served as
Vice President, Chief Accounting Officer and Corporate Controller
at ViroPharma Incorporated. Mr. Kirby began his career at
KPMG, LLP and served as a Regional Audit Director at AstraZeneca
Pharmaceuticals prior to joining ViroPharma. Mr. Kirby
received his Bachelor of Science from Villanova University and is a
licensed certified public accountant.
About Idera Pharmaceuticals Idera
Pharmaceuticals is a clinical-stage patient focused
biopharmaceutical company developing novel therapeutic approaches
for the treatment of cancer and rare diseases. Idera’s proprietary
technology involves creating novel nucleic acid therapeutics.
Idera’s immunotherapy approach is based on the modulation of
Toll-like receptors (TLRs). In addition to its TLR modulation
programs, Idera is developing gene silencing oligonucleotides (GSO)
technology that it has created to inhibit the production of
disease-associated proteins by targeting RNA. To learn more about
Idera, visit www.iderapharma.com.
Investor and Media Contact
Robert Doody
Vice President, Investor Relations and Corporate Communications
Office: 617-679-5515
Mobile: 484‐639‐7235
rdoody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Sep 2023 to Sep 2024